Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.79 |
| ▸ | KDR | P35968 | 14/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31362715 | 0.92 | KDR (0.79) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL6105689 | 0.90 | KDR (0.81) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL15528935 | 0.88 | KDR (0.84) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL16625628 | 0.88 | KDR (0.84) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL18048949 | 0.88 | KDR (0.84) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL15528901 | 0.87 | KDR (0.87) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL6104460 | 0.87 | KDR (0.69) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL18049886 | 0.85 | KDR (0.83) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL446910 | 0.85 | KDR (0.81) | MEN1MAPTKMT2AKDM4EL3MBTL1 | |
| SCHEMBL6104906 | 0.84 | PDPK1 (0.63) | MEN1MAPTKMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2846803-B1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ALPHARMAGEN LLC (US) | 2017-06-21 | — | — | EP | claimed |
| US-20150099758-A1 | Alpha 7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ANVYL LLC (US) | 2015-04-09 | — | — | US | claimed |
| EP-2846803-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2015-03-18 | — | — | EP | claimed |
| WO-2013169889-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-11-14 | — | — | WO | claimed |
| EP-2846803-B1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ALPHARMAGEN LLC (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2846803-B1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ALPHARMAGEN LLC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20150099758-A1 | Alpha 7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ANVYL LLC (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099758-A1 | Alpha 7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ANVYL LLC (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099758-A1 | Alpha 7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ANVYL LLC (US) | 2015-04-09 | — | — | US | disclosed |
| EP-2846803-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013169889-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099758-A1 | Alpha 7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | CHRNA7, CHRNA1, CHRNA2 | MEN1 4409/4885MAPT 1991/4885KMT2A 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.